Evaluation of Aqueous Humor DEL-1 and IL-17 Levels in Diabetic Cataract Patients

Launched by UŞAK UNIVERSITY · May 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at the levels of two specific substances, DEL-1 and IL-17, in the eye fluid of patients with diabetic cataracts compared to those without diabetes. The goal is to understand how diabetes can cause inflammation in the eye, which may help improve treatments for cataracts in diabetic patients.

To participate, you must be diagnosed with cataracts and scheduled for surgery, and if you have diabetes, it should be type 2 and diagnosed for at least five years. However, you cannot have any other eye conditions, previous eye surgeries, or certain health issues. If eligible, you can expect to provide a small sample of eye fluid during your surgery, which will help researchers learn more about the effects of diabetes on eye health. This study is currently recruiting participants aged between 18 and 80, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Cataract diagnosed and surgery planned
• • Patients without any other ocular pathology other than cataract.
• • Type 2 DM for at least 5 years in the diabetic group
• Exclusion Criteria:
• • Patients with previous intraocular surgery
• • Those with inflammatory eye diseases (e.g. uveitis)
• • Those with autoimmune diseases or systemic inflammatory diseases
• • Those receiving local or systemic steroid therapy
• • Those with severe systemic disease (e.g. advanced renal failure, malignancy)